DaVita Inc. and Fresenius Medical Care North America (FMCNA) jointly announced they are collaborating in response to the COVID-19 pandemic to offer isolation capacity for dialysis patients who are or may be infected with the novel coronavirus that causes the disease. The companies, which are the largest providers of dialysis in the United States, also…
Physicians at the University of California Irvine describe an unusual presentation of the novel coronavirus illness in a 56-year-old man. The case is believed to be among the first COVID-19 cases in the United States.
Dialysis facilities have stepped up precautions to protect patients with kidney failure from COVID-19, which can cause severe respiratory illness and death.
Febuxostat is safe and effective for treating gout in patients on dialysis, according to a new study. The study was a retrospective review of clinical and laboratory data from 62 dialysis patients (45 on hemodialysis and 17 on peritoneal dialysis) with gout treated with febuxostat. The mean serum uric acid level decreased significantly from 9.36…
Lower use of anticoagulants may partially explain why black, Hispanic, and Asian hemodialysis patients with atrial fibrillation have higher stroke rates than their white counterparts, a study suggests.
Investigators found no meaningful survival difference between patients transitioning to home hemodialysis or peritoneal dialysis within 12 months of dialysis initiation.
Back in August 2012, I wrote a provocative editorial in this space titled, “How About Twice-Weekly Hemodialysis?” This was the first time the topic of dialysis provided less frequently than 3 times a week was brought up in the 21st century. I argued that because kidney function worsens gradually, dialysis treatment should be gradual and…
Patients starting on peritoneal dialysis or in-center hemodialysis have similar mortality risks, according to a new systematic review and meta-analysis of studies using propensity score matching to compare mortality risks between the modalities.
